Skip to main content

Table 1 Population-based and clinical samples

From: Shared genetic influences between dimensional ASD and ADHD symptoms during child and adolescent development

Sample Source Ethnicity Number Phenotype/diagnosis
ALSPACa,b General population White European 5612 (7 y): age(SE) = 6.79(0.11) ADHD symptoms (mother-report) as assessed with SDQ ADHD scores
5678 (10 y): age(SE) = 9.65(0.12)
5259 (12 y): age(SE) = 11.72(0.13)
5072 (13 y): age(SE) = 13.16(0.18)
4164 (17 y): age(SE) = 16.84(0.18)
ALSPACa,b General population White European 5551 (8 y): age(SE) = 7.65(0.14) Social-communication difficulties (mother-report) as assessed with SCDC scores
5460 (11 y): age(SE) = 10.72(0.13)
5060 (14 y): age(SE) = 13.90(0.15)
4174 (17 y): age (SE) = 16.84(0.36)
PGC-ADHDc Clinical ADHD sample White European 4163 cases and 12,040 controls/pseudo-controls ADHD or hyperkinetic disorder
PGC-ASDa Clinical ASD sample White European 5305 cases; 5305 pseudo-controls ASD
  1. ADHD attention deficit hyperactivity disorder, ALSPAC Avon Longitudinal study of Parents and Children, ASD autism spectrum disorder, PGC-ADHD ADHD collection of the Psychiatric Genomics Consortium (PGC), PGC-ASD ASD collection of the PGC, SCDC Social and Communication Disorders Checklist, SDQ-ADHD ADHD subscale of the Strength and Difficulties Questionnaire, y age in years
  2. aSamples were imputed to a 1000 genomes reference (Phase1_v3)
  3. bALSPAC individuals who were related to participants of the PGC-ADHD sample were excluded
  4. cSamples were imputed to HapMap3 CEU and TSI